FDA approves tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes – Cardiovascular Business Posted on August 28, 2026 By Malcolm Knoll No Comments on FDA approves tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes – Cardiovascular Business FDA Approves Tirzepatide for Reducing Cardiovascular Risk in Adults with Type 2 Diabetes Cardiovascular Business FDA has approved tirzepatide for lowering cardiovascular risk in adults with type 2 diabetes. Business